NCT01674673

Brief Summary

It is known that the treatment of panic disorder with medication and psychotherapy are both effective. Representative as a treatment for panic disorder, Selective serotonin reuptake inhibitors (SSRIs) are recommended as first-line treatment of panic disorder. In general, the initial reaction rate of panic disorder medication known to be frequently stopped early recurrence 70-80% It's too early, it is recommended that the duration of drug treatment for at least one year to be long-lasting. But whether it is appropriate for the duration of drug treatment to maintain a certain extent remains controversial, and maintain the medication for more than one year, even if the long-term effects known to be approximately 50% less than beyond being negative when remission based. Meanwhile, the typical method for the treatment of panic disorder psychology, cognitive behavioral therapy (Cognitive behavioral therapy) and looked comparable to the effect of the drug in the treatment of the known, especially in recent years when the combined treatment with medication can increase the long-term treatment of sexual reported that there's has been the subject of attention. But prospectively compare the long-term effects of these two treatments, research, especially the research about the long-term effects of the combined treatment with the drug treatment of panic disorder is very low, and almost nil is Researchers, drug treatment and the effect of the combined treatment in patients with panic disorder over two years prospective study to compare the plans were. And verification, the researchers performed only through this study by comparing the long-term effects of the combined treatment with medication combined treatment of medication to be more effective than if the reaction to the long-term treatment of panic disorder that can affect the clinical and biological factors navigate to evaluate them. In addition, long-term observational study, panic disorder patients' subjective quality of life actually improved to some extent on the map together proven to.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
110

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Feb 2012

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2012

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

August 24, 2012

Completed
5 days until next milestone

First Posted

Study publicly available on registry

August 29, 2012

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2014

Completed
Last Updated

December 30, 2013

Status Verified

August 1, 2012

Enrollment Period

2.7 years

First QC Date

August 24, 2012

Last Update Submit

December 26, 2013

Conditions

Keywords

panic disorderSSRIs pharmacotherapyCognitive Behavioral therapy

Outcome Measures

Primary Outcomes (1)

  • PDSS

    one year

Eligibility Criteria

Age20 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Panic disorder patients 20 years of age or older to visit the Samsung Seoul Hospital, and the Department of Mental Health, a foreign patients, patients who agreed to participate in this study will be of. Plan the patient-specific total of 100 patients on each drug treatment group and combined treatment group, 55 patients recruited by the first year of study commences 1 years F / U to enforce the number of subjects.

You may qualify if:

  • Outpatients with panic disorder at the SMC
  • PD patients who agree to participate in the clinical study
  • PD patients who are over 20 years old

You may not qualify if:

  • PD patients who have either severe medical illnesses or other psychiatric illnesses
  • PD patients who are pregnant, or lactating
  • PD patients who have suicidal idea

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Samsung Medical Center

Seoul, Seoul, 000000, South Korea

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

whole blood

MeSH Terms

Conditions

Panic Disorder

Condition Hierarchy (Ancestors)

Anxiety DisordersMental Disorders

Study Officials

  • BumHee BH Yu, Ph.D

    Samsung Medical Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Bum-Hee Yu, MD, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 24, 2012

First Posted

August 29, 2012

Study Start

February 1, 2012

Primary Completion

October 1, 2014

Study Completion

October 1, 2014

Last Updated

December 30, 2013

Record last verified: 2012-08

Locations